Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Inclusion Criteria:
Exclusion Criteria:
Patient had received previous treatment with BKM120 Patient had symptomatic CNS metastases Patient had mood disorder as outlined in Section 5 Patient had received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug.
Norwich, Connecticut 06360, United States
Chicago, Illinois 60611, United States
Schaumburg, Illinois 60173, United States
South Bend, Indiana 46617, United States
Ann Arbor, Michigan 48109 5271, United States
Grand Rapids, Michigan 49546, United States
Minneapolis, Minnesota 55404, United States
Morristown, New Jersey 07962, United States
Chapel Hill, North Carolina 27599-7600, United States
Portland, Oregon 97239, United States
Willow Grove, Pennsylvania 19090, United States
Sioux Falls, South Dakota 57104, United States
Chattanooga, Tennessee 37404, United States
Houston, Texas 77030, United States
San Antonio, Texas 78229, United States
Roanoke, Virginia 24018, United States
Kennewick, Washington 99336, United States